---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030563"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:39:21.712930+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harrow Q2 2024 record revenue $48.9M (+46% YoY); adj EBITDA $8.8M; guides FY rev >$180M

## Summary
- Record Q2 revenue $48.9M, up 46% YoY and 42% sequentially; GAAP net loss $(6.5)M.
- Adjusted EBITDA $8.8M; core gross margin 79% (up from 78%).
- IHEEZO unit demand up 98% QoQ; VEVYE prescriptions up 212% QoQ; new IHEEZO supply agreements.
- FY2024 revenue guidance >$180M (excluding TRIESENCE); expects back-half outperformance.
- TRIESENCE PPQ Batch 2 passes initial tests; third batch scheduled; potential 2024 relaunch.

## SEC filing metadata
- accession: 0001493152-24-030563
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315224030563/0001493152-24-030563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315224030563/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030563
- JSON: https://secwatch.observer/filing/0001493152-24-030563.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.